Skip to main content

Acrivon Therapeutics, Inc.

ACRV
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001781174

In the last 90 days, Acrivon Therapeutics, Inc. insiders filed 0 open-market purchases and 8 sales; 46 institutions reported holding it in 13F filings for Q2 2026, worth $38.1M in total; no superinvestor holds it.

Q2 2025 vs. Q1 2025

How the institutions holding Acrivon Therapeutics, Inc. changed between Q1 2025 and Q2 2025.

All holders in Q2 2025All holders in Q1 2025

13F holders of ACRV: Q1 2025 compared with Q2 2025
MeasureQ1 2025Q2 2025Change
Holders6353−10
Shares22.5M17.8M−4.73M (−21.0%)
Value$45.7M$21.2M−$24.6M (−53.7%)

New holders (15)

Institutions that held Acrivon Therapeutics, Inc. at the end of Q2 2025 but not at the end of Q1 2025.

Institutions new to ACRV in Q2 2025
InstitutionSharesValue% of portfolio
Jacobs Levy Equity Management, Inc382,234$454.9K0.00%
Jane Street Group, LLC311,829$371.1K0.00%
Millennium Management LLC296,239$352.5K0.00%
Two Sigma Investments, LP181,172$215.6K0.00%
Squarepoint Ops LLC152,605$181.6K0.00%
HRT Financial LP145,895$173.0K0.00%
XTX Topco Ltd106,119$126.3K0.01%
Two Sigma Advisers, LP32,600$38.8K0.00%
AQR Capital Management LLC22,252$26.5K0.00%
Quadrature Capital Ltd22,175$26.3K0.00%
SG Americas Securities, LLC15,265$18.0K0.00%
Qube Research & Technologies Ltd12,692$15.1K0.00%
Ground Swell Capital, LLC12,215$14.5K0.02%
Federated Hermes, Inc.2,318$2.76K0.00%
Russell Investments Group, Ltd.481$5720.00%

Sold out (25)

Institutions that held Acrivon Therapeutics, Inc. at the end of Q1 2025 and filed for Q2 2025 without it.